Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Spectral AI, Inc. is a medical technology company operating in the healthcare technology and artificial intelligence–enabled diagnostics industries. The company focuses on developing predictive analytics tools that assist clinicians in assessing tissue viability and healing potential, with an initial emphasis on burn care. Its core technology applies advanced imaging and machine learning to support objective clinical decision-making in acute care settings.
The company’s primary commercial and developmental focus is the DeepView® System, an AI-powered imaging platform designed to predict burn wound healing outcomes earlier than traditional clinical assessment. Spectral AI primarily serves hospitals, burn centers, and government agencies involved in trauma and emergency medicine. Its strategic positioning centers on being one of the first companies to combine multispectral imaging with AI for wound assessment, supported by U.S. government funding and regulatory designations. Founded in 2004 under the name Spectral MD, the company evolved from research-focused origins into a clinical-stage AI diagnostics firm and became publicly listed on Nasdaq in 2023 following a business combination.
Business Operations
Spectral AI operates primarily through a single reportable business focused on AI-based medical imaging and predictive diagnostics. Revenue generation to date has largely been driven by research and development contracts, particularly non-dilutive funding from U.S. government agencies, rather than broad commercial sales. The company’s operations include the development, validation, and regulatory advancement of its proprietary imaging hardware, software algorithms, and clinical data platforms.
The company conducts operations in both the United States and the United Kingdom, supporting clinical trials, data collection, and algorithm training. Its technology portfolio includes proprietary datasets, AI models, and optical imaging systems designed for point-of-care use. Spectral AI maintains contractual relationships with government entities and clinical research institutions, and its intellectual property is held within wholly owned operating subsidiaries. Data on additional joint ventures or material commercial partnerships beyond government-sponsored programs is inconclusive based on available public sources.
Strategic Position & Investments
Spectral AI’s strategic direction is focused on obtaining regulatory clearance and expanding the clinical indications for the DeepView® System, with the goal of commercial deployment in hospital settings. A key growth initiative is the pursuit of U.S. Food and Drug Administration authorization, supported by its designation under the FDA’s Breakthrough Devices Program. The company has also emphasized scaling its AI models through expanded clinical datasets and real-world evidence generation.
A significant component of its strategy includes continued collaboration with U.S. government agencies, including long-term contracts related to emergency preparedness and trauma care. Spectral AI has not disclosed a broad acquisition strategy, and there is no verified evidence of material acquisitions or a diversified investment portfolio as of the most recent public filings. Its investments are primarily internal, directed toward product development, regulatory compliance, and clinical validation within emerging AI-driven diagnostics.
Geographic Footprint
Spectral AI is headquartered in the United States, with principal executive offices in Texas, and maintains a substantial operational presence in the United Kingdom. These locations support research, clinical trials, data science, and regulatory activities. The company’s geographic footprint reflects its reliance on both U.S. healthcare infrastructure and U.K.-based clinical research collaborations.
While the company does not currently report broad commercial distribution across multiple continents, its technology development and regulatory strategy are oriented toward eventual expansion into additional international healthcare markets. Its global influence to date has been primarily through research collaborations and government-funded programs rather than direct sales operations.
Leadership & Governance
Spectral AI is led by an executive team with backgrounds in medical technology, data science, and healthcare commercialization. The leadership emphasizes a strategy centered on scientific validation, regulatory rigor, and the responsible deployment of AI in clinical environments. Governance practices align with U.S. public company standards following its Nasdaq listing.
Key executives include:
- Wensheng Fan, PhD – Chief Executive Officer
- Danny Harris – Chief Financial Officer
- Dr. J. Michael DiMaio – Chief Medical Officer
- Brian VanDusen – Chief Operating Officer
Information regarding the original founder(s) and detailed leadership philosophy beyond publicly stated strategic priorities is limited; data inconclusive based on available public sources.